Aktuelle Nachrichten zu Adaptive Biotechnologies
Portfoliocheck: Fidelity National Information Services ist Andreas Halvorsens Trumpf im War on Cash
Ole Andreas Halvorsen managt in seinem Viking Global Hedgefonds mehr inzwischen als 27 Milliarden Dollar und erzielte in den vergangenen 19 Jahren für seine Anleger eine durchschnittliche Jahresrendite...
IPO-RADAR (HF Enterprise, Inhibikase Therapeutics, In8Bio, The RealReal,...)
Das der Optimismus bei den US-Unternehmen weiter hoch, zeigen die Börsengänge in dieser Woche. Zwei Biotech- und zwei Finanzierungsunternehmen wollen den Sprung an die Börse wagen.- ‹
- 1
- ›
Aktuelle Nachrichten anderer Redaktionen zu Adaptive Biotechnologies
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Lets find out.
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?
The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year.
Adaptive Biotechnologies stock soars on Q1 earnings beat By Investing.com
Adaptive Biotechnologies stock soars on Q1 earnings beat
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 11.54% and 2.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Wir finden für unsere Leser softwaregestützt die besten Aktien der Welt
und schreiben darüber, wie man diese handeln muss, um Geld zu verdienen.